774 reports of this reaction
1.5% of all DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS reports
#11 most reported adverse reaction
PRURITUS is the #11 most commonly reported adverse reaction for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, manufactured by Accord Healthcare, Inc.. There are 774 FDA adverse event reports linking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS to PRURITUS. This represents approximately 1.5% of all 50,803 adverse event reports for this drug.
Patients taking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS who experience pruritus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRURITUS is a less commonly reported adverse event for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, but still significant enough to appear in the safety profile.
In addition to pruritus, the following adverse reactions have been reported for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS:
The following drugs have also been linked to pruritus in FDA adverse event reports:
PRURITUS has been reported as an adverse event in 774 FDA reports for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRURITUS accounts for approximately 1.5% of all adverse event reports for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, making it a notable side effect.
If you experience pruritus while taking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.